BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Stressgen Biotechnologies Corporation (SSB.TO) Obtains Securityholder Approval For Corporate Transaction


3/17/2006 10:37:44 AM

VICTORIA and SAN DIEGO, CA, March 16 /PRNewswire-FirstCall/ - Stressgen Biotechnologies Corporation ("Stressgen") announced today that the corporate reorganization involving Stressgen and 0747036 B.C. Ltd. ("Investor"), an affiliate of Madison Group, a diversified investment firm, has been approved by Stressgen's securityholders. The transaction was previously announced on January 30, 2006.

Following completion of the transaction, Newco (which will then be named "Stressgen Biotechnologies Corporation") will continue to carry on the business currently carried on by Stressgen, but will have the benefit of up to an additional $9.25 million non-dilutive capital. The current board and management of Stressgen will carry on in the same capacity with Newco. In addition, as part of the reorganization, Newco will retain Stressgen's current listing and stock symbol (SSB) on the Toronto Stock Exchange (TSX).

Upon completion of the transaction, the Investor will rename the existing Stressgen entity "GVIC Publications Ltd." ("GVIC Publications"), elect a new board of directors and seek fresh capital and new business opportunities. The Investor will hold a 94.9 percent equity interest in, and current Stressgen shareholders will hold a 5.1 percent equity interest in, GVIC Publications.

The closing of the corporate transaction remains subject to the satisfaction of certain conditions precedent, including receipt of court and regulatory approvals. Provided that all of the conditions precedent are satisfied or waived by the appropriate parties, Stressgen currently anticipates completing the transaction on or about March 23, 2006.

About Stressgen Biotechnologies Corporation:

--------------------------------------------

Stressgen is developing innovative therapeutics for the treatment of viral infections, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol SSB. For more information about Stressgen, please visit the website located at www.stressgen.com.

This press release contains forward-looking statements regarding a corporate reorganization, by way of a plan of arrangement, and development of our HspE7 program. Actual results could be materially different from those implied by these forward-looking statements due to factors over which we have limited control, including but not limited to the risk that the reorganization may not be consummated, for any number of reasons, including the failure to obtain necessary court approvals or the failure to satisfy all of the closing conditions, our ability to continue as a going concern, our ability to enter into corporate partnering relationships (and the effects and terms of those relationships), difficulties inherent in the manufacture of commercial-grade clinical supplies, our ability to meet regulatory approval requirements, the development of our potential products, including HspE7, not proceeding as planned, clinical trial uncertainties, the risk that, if successfully developed, HspE7 may not be commercially successful and the effect of our limited cash resources. Please refer to our filings with Canadian securities regulators for more information on these and other applicable risks. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

Stressgen Contact: ------------------ Donna Slade Director, Investor Relations 6055 Lusk Boulevard San Diego, CA USA 92121 Tel: 858/202-4900 Dir: 858/202-4945 Fax: 858/450-6849 dslade@stressgen.com

Stressgen Biotechnologies Corp.

CONTACT: Stressgen Contact: Donna Slade, Director, Investor Relations,6055 Lusk Boulevard, San Diego, CA, USA, 92121, Tel: (858) 202-4900, Dir:(858) 202-4945, Fax: (858) 450-6849, dslade@stressgen.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES